Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Executive Officer

Chief Commercial Officer

COO, CFO and President

SVP, Chief Accounting Officer

Chief Innovation Officer

Chief Legal Officer

SVP, Global Regulatory Affairs

EVP, Chief R&D Officer

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for p...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2023-09-26	Premium	back to issuer	Premium	Premium	Premium	-
2023-09-26	Premium	back to issuer	Premium	Premium	Premium	Chief Executive Officer
2023-09-26	Premium	back to issuer	Premium	Premium	Premium	-
2023-09-26	Premium	back to issuer	Premium	Premium	Premium	-
2023-09-26	Premium	back to issuer	Premium	Premium	Premium	-
2023-09-26	Premium	back to issuer	Premium	Premium	Premium	Chief Commercial Officer
2023-09-26	Premium	back to issuer	Premium	Premium	Premium	-
2023-09-26	Premium	back to issuer	Premium	Premium	Premium	-
2023-09-26	Premium	back to issuer	Premium	Premium	Premium	-
2023-09-26	Premium	back to issuer	Premium	Premium	Premium	-
2023-09-26	Premium	back to issuer	Premium	Premium	Premium	COO, CFO and President
2023-09-26	Premium	back to issuer	Premium	Premium	Premium	SVP, Chief Accounting Officer
2023-09-26	Premium	back to issuer	Premium	Premium	Premium	-
2023-09-26	Premium	back to issuer	Premium	Premium	Premium	-
2023-09-26	Premium	back to issuer	Premium	Premium	Premium	-
2023-09-26	Premium	back to issuer	Premium	Premium	Premium	-
2023-09-26	Premium	back to issuer	Premium	Premium	Premium	-
2023-09-26	Premium	back to issuer	Premium	Premium	Premium	-
2023-09-26	Premium	back to issuer	Premium	Premium	Premium	-
2023-09-26	Premium	back to issuer	Premium	Premium	Premium	-
2023-09-26	Premium	back to issuer	Premium	Premium	Premium	Chief Executive Officer
2023-09-26	Premium	back to issuer	Premium	Premium	Premium	-
2023-09-26	Premium	back to issuer	Premium	Premium	Premium	Chief Innovation Officer
2023-09-26	Premium	back to issuer	Premium	Premium	Premium	-
2023-09-26	Premium	back to issuer	Premium	Premium	Premium	-

RETA - Reata Pharmaceuticals Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for RETA